The US Food and Drug Administration has approved the new drug Cobenfy, which is owned by pharmaceutical firm Bristol Myers ...

At 8:45 a.m. ET, Dow E-minis were up 90 points, or 0.21%, S&P 500 E-minis were up 10.5 points, or 0.18% and Nasdaq 100 ...

Even so, the drug offers a promising alternative for the millions of Americans who suffer from this condition. Bristol Myers Squibb is also testing the drug in other disease-related psychosis, ...

A Commerce Department report, due at 8:30 a.m. ET, is expected to show the Personal Consumption Expenditure Index - the Fed's ...

Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This ...

The Bristol Myers Squibb medicine is said relieve symptoms without causing some of the harsh side effects of drugs already in use. Meanwhile, thousands of patients allege in a lawsuit that drugs used ...

Data through the week points to a still-resilient economy overall, leaving traders uncertain about the Fed’s next move.

Stock futures were modestly higher ahead of the release of the Federal Reserve's preferred measures of inflation, as major ...

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.

Jeffrey Rubin, the president and director of research at Westport, Conn.-based Birinyi Associates - who now owns the firm following the death of the legendary Laszlo Birinyi - is among those who is ...

The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and ...

Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The ...